1. Wilson SAK. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295–507.
2. Frerichs FT. A Clinical Treatise on Diseases of the Liver. London: The New Sydenham Society, 1860.
3. Westphal C. Über eine dem Bilde der cerebrospinalen grauen Degeneration ähnliche Erkrankung des centralen Nervensystems ohne anatomischen Befund, nebst einigen Bermerkungen über paradoxe Contraction. Arch Psychiatr Nervenkrank 1883;14:87–134.
4. Gowers W. A Manual of Diseases of the Nervous System. London: J & A Churchill, 1988.
5. Ormerod JA. Cirrhosis of the liver in a boy, with obscure and fatal nervous symptoms. St Bart Hosp Rep 1890;XXVI:57.
6. Homen EA. Eine Eigenthümliche bei drei Geschwistern auftretende typische Krankheit unter der Form einer progressiven Dementia, in Verbindung mit ausgedehnten Gefässveränderungen (wohl lues hereditaria tarda). Arch Psychiatr 1892;XXIV:191–228.
7. Strümpell A. über die Westphal'sche Pseudosklerose und über diffuse Hirnsklerose, inbesondere bei Kindern. Dtsch Z Nervenheilk 1898;12:115–149.
8. Kayser B. Über einen Fall von angeborener grünlicher Verfärbung der Kornea. Klin Monatsbl Augenheilkd 1902;40:22–25.
9. Fleischer B. Zwei weiterer Falle von grünlicher Verfärbung der Kornea. Klin Monatsbl Augenheilkd 1903;41:489–491.
10. Fleischer B. Über eine der “Pseudosklerose” nahestehende, bisher unbekannte Krankheit (gekennzeichnet durch tremor, psychische storungen, braunliche Pigmentierung bestimmter gewebe, inbesondere auch der Hornhautperipherie, Lebercirrhose). Dtsch Z Nervenheilkd 1912;44:179–201.
11. Rumpel A. Über das Wesen und die Bedeutung der Leberveränderungen und der Pigmentierunen bei den damit verbundenen Fällen von Pseudosklerose, zugleich ein Beitrag zur Lehre von der Pseudosklerose (Westphal-Strümpell). Dtsch Z Nervenheilkd 1913;49:54–73.
12. Mandelbrote BM, Stanier MW, Thompson RHS, et al. Studies on copper
metabolism in demyelinating diseases of the central nervous system. Brain 1948;71:212–228.
13. Cumings JN. The copper
and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 1948;71:410–415.
14. Scheinberg IH and Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 1952;116:484–485.
15. Bearn AG and Kunkel HG. Biochemical abnormalities in Wilson's disease. J Clin Invest 1952;31:616.
16. Frommer DJ. Defective biliary excretion of copper
in Wilson's disease. Gut 1974;15:125–129.
17. Hall HC. La Dégénérescence Hépato-lenticulaire: Maladie de Wilson-Pseudosclérose. Paris: Paul Masson, 1921.
18. Scheinberg IH and Sternlieb I: Wilson's Disease. Philadelphia: WB Saunders, 1984.
19. Mak CM and Lam C-W: Diagnosis of Wilson's disease: a comprehensive review. Crit Rev Clin Lab Sci 2008;45:263–290.
20. Meenakshi-Sundaram S, Mahadevan A, Taly AB, et al. Wilson's disease: A clinico-neuropathological autopsy study. J Clin Neurosci 2008;15:409–417.
21. Reilly M, Daly L, and Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland. J Neurol Neurosurg Psychiatry 1993;56:298–300.
22. Brewer GJ. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston: Kluwer, 2001.
23. Olivarez L, Caggana M, Pass KA, et al. Estimate of the frequency of Wilson's disease in the US Caucasian population: A mutation analysis approach. Ann Hum Genet 2001;65:459–463.
24. Frydman M, Bonné-Tamir B, Farrer LA, et al. Assignment of the gene for Wilson's disease to chromosome 13. Proc Natl Acad Sci U S A 1985;82:1819–1821.
25. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper
transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327–337.
26. Petrukhin K, Fischer SG, Piratsu M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993;5:338–343.
27. Yamaguchi Y, Heiny ME, and Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993;197:271–277.
28. Petrukhin K, Lutsenko S, Chernov I, et al. Characterization of the Wilson's disease gene encoding a P-type copper
transporting ATPase: Genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994;3:1647–1656.
29. Terada K, Schilsky M, Miura N, et al. ATP7B (WND) protein. Int J Biochem Cell Biol 1998;30:1063–1067.
30. Lutsenko S, Petrukhin K, Cooper MJ, et al. N-Terminal domains of human copper-transporting adenosine
triphosphatases (the Wilson's and Menkes disease proteins) bind copper
selectively in vivo and in vitro with stoichiometry of one copper
per metal-binding repeat. J Biol Chem 1997;272:18939–18944.
31. DiDonato M, Narindrasorasak S, Forbes JR, et al. Expression, purification, and metal binding properties of the N-terminal domain from the Wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem 1997;272:33279–33282.
32. Hung IH, Suzuki M, Yamaguchi Y, et al. Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae. J Biol Chem 1997;272:21461–21466.
33. La Fontaine S, Theophilos MB, Firth SD, et al. Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper
ATPase. Hum Mol Genet 2001;10:361–370.
34. Forbes JR and Cox DW. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins. Hum Mol Genet 2000;9:1927–1935.
35. Weiss KH, Wurz J, Gotthardt D, et al. Localization of the Wilson disease protein in murine intestine. J Anat 2008;213:232–240.
36. Wilson AM, Schlade-Bartusiak K, Tison JL, et al. A minigene approach for analysis of ATP7B splice variants in patients with Wilson disease. Biochimie 2009 [epub ahead of print].
37. Loudianos G, Lovicu M, Dessi V, et al. Abnormal mRNA splicing resulting from consensus sequence splicing mutations of ATP7B. Hum Mutat 2002;20:260–266.
38. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper
transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993;5:44–50.
39. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: Spectrum of mutations and their consequences. Nat Genet 1999;9:210–217.
40. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): Population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997;61:317–328.
41. Czlonkowska A, Gromadzka G, and Chabik G. Monozygotic female twins discordant for phenotype of Wilson's disease. Mov Disord 2009;24:1066–1069.
42. Peña MMO, Lee J, and Thiele DJ. A delicate balance: Homeostatic control of copper
uptake and distribution. J Nutr 1999;129:1251–1260.
43. Roberts EA and Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper
. Am J Clin Nutr 2008;88(suppl):851S–854S.
44. Roberts EA and Schilsky ML. Diagnosis and treatment of Wilson disease: An update. Hepatology 2008;47:2089–2111.
45. Reddy PV, Rao KV, and Norenberg MD. The mitochondrial permeability transition, and oxidative and nitrosative stress in the mechanism of copper
toxicity in cultured neurons and astrocytes. Lab Invest 2008;88:816–830.
46. Goyal MK, Sinha S, Patil SA, et al. Do cytokines have any role in Wilson's disease? Clin Exp Immunol 2008;154:74–79.
47. Holmberg CG and Laurell CB. Investigations in serum copper
. II. Isolation of the copper
containing protein and a description of some of its properties. Acta Chem Scand 1948;2:550–556.
48. Shiono Y, Wakusawa S, Hayashi H, et al. Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol 2001;96:3147–3151.
49. Sato M, Schilsky ML, Stockert RJ, et al. Detection of multiple forms of human ceruloplasmin: A novel Mr 2,000,000 form. J Biol Chem 1990;265:2533–2537.
50. Gibbs K and Walshe JM. A study of the ceruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups. Q J Med 1979;48:447–463.
51. Yang F, Naylor SL, Lum JB, et al. Characterization, mapping, and expression of the human ceruloplasmin gene. Proc Natl Acad Sci U S A 1986;83:3257–3261.
52. Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family. Ann Neurol 1995;37:646–656.
53. Hellman NE and Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439–458.
54. Jones RJ, Lewis SJ, Smith JM, et al. Undetectable serum ceruloplasmin in a woman with chronic hepatitis C infection. J Hepatol 2000;32:703–704.
55. van Berge Henegouwen GP, Tangedahl TN, Hofman AF, et al. Biliary secretion of copper
in healthy man. Gastroenterology 1977;72:1228–1231.
56. O'Reilly S, Weber PM, Oswald H, et al. Abnormalities of the physiology of copper
in Wilson's disease. Arch Neurol 1971;25:28–32.
57. Owen CA Jr. Absorption and excretion of Cu64
by the rat. Am J Physiol 1964;207:1203–1206.
58. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003;23:139–142.
59. Aggarwal A, Aggarwal N, Nagral A, et al. A novel global assessment scale for Wilson's disease (GAS for WD). Mov Disord 2009;24:509–518.
60. Czlonkowska A, Tarnacka B, Möller JC, et al. Unified Wilson's Disease Rating Scale – a proposal for the neurological scoring of Wilson's disease patients. Neurol Neurochir Pol 2007;41:1–12.
61. Leinweber B, Möller JC, Scherag A, et al. Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Mov Disord 2008;23:54–62.
62. Walshe JM. Wilson's disease: The presenting symptoms. Arch Dis Child 1962;37:253–256.
63. Chu N-S and Hung T-P. Geographic variations in Wilson's disease. J Neurol Sci 1993;117:1–7.
64. Walshe JM. Wilson's disease (HLD), in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Vol 27. Amsterdam: North-Holland, 1976, pp. 379–414.
65. Gow PJ, Smallwood RA, Angus PW, et al. Diagnosis of Wilson's disease: An experience over three decades. Gut 2000;46:415–419.
66. Czlonkowska A, Rodo M, and Gromadzka G. Late onset Wilson's disease: Therapeutic implications. Mov Disord 2008;23:896–898.
67. Sternlieb I and Scheinberg IH. Chronic hepatitis as a first manifestation of Wilson's disease. Ann Intern Med 1972;76:59–64.
68. Scott J, Gollan JL, Samourian S, et al. Wilson's disease presenting as chronic active hepatitis. Gastroenterology 1978;74:645–651.
69. Lech T, Hydzik P, and Kosowski B. Significance of copper
determination in late onset of Wilson's disease. Clin Toxicol (Phila) 2007;45:688–694.
70. Schilsky ML, Scheinberg IH, and Sternlieb I. Liver transplantation for Wilson's disease: Indications and outcome. Hepatology 1994;19:583–587.
71. Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology 2008;48:1167–1174.
72. Enomoto K, Ishibashi H, Irie K, et al. Fulminant hepatic failure without evidence of cirrhosis in a case of Wilson's disease. Jpn J Med 1989;28:80–84.
73. Roche-Sicot J and Benhamou J-P. Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med 1977;86:301–303.
74. Hoshino T, Kumasaka K, Kawano K, et al. Low serum alkaline phosphatase activity associated with severe Wilson's disease. Is the breakdown of alkaline phosphatase molecules caused by reactive oxygen
species? Clin Chim Acta 1995;238:91–100.
75. Kenngott S and Bilzer M. Inverse correlation of serum bilirubin and alkaline phosphatase in fulminant Wilson's disease. J Hepatol 1998;29:683.
76. Markiewicz-Kijewska M, Szymczak M, Ismali H, et al. Liver transplantation for fulminant Wilson's disease in children. Ann Transplant 2008;13:28–31.
77. Strickland GT and Leu ML. Wilson's disease: Clinical and laboratory manifestations in 40 patients. Medicine 1975;54:113–137.
78. Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis, and long-term outcome of Wilson's disease: a cohort study. Gut 2007;56:115–120.
79. Ross E, Jacobson IM, Dienstag JL, et al. Late onset Wilson's disease with neurologic involvement in the absence of Kayser-Fleischer rings. Ann Neurol 1985;17:411–413.
80. Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005;41:668–670.
81. Walshe JM. Wilson's disease. In Vinken PJ, Bruyn GW, Klawans HL (eds). Handbook of Clinical Neurology. Vol 49. New York: Elsevier, 1986, pp. 223–238.
82. Topaloglu H and Renda Y. Tongue dyskinesia in Wilson disease. Brain Dev 1992;14:128.
83. Topaloglu H, Gucuyener K, Orkun C, et al. Tremor of tongue and dysarthria as the sole manifestation of Wilson disease. Clin Neurol Neurosurg 1990;92:295–296.
84. Nicholl DJ, Ferenci P, Polli C, et al. Wilson's disease presenting in a family with an apparent dominant history of tremor. J Neurol Neurosurg Psychiatry 2001;70:514–516.
85. Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: Report of 119 cases. Mov Disord 2006;21:2192–2196.
86. Parker N. Hereditary whispering dysphonia. J Neurol Neurosurg Psychiatry 1985;48:218–224.
87. Cartwright GE. Diagnosis of treatable Wilson's disease. N Engl J Med 1978;298:1347–1350.
88. da Silva-Júnior FP, Carrasco AEAB, da Silva Mendes AM, et al. Swallowing dysfunction in Wilson's disease: A scintigraphic study. Neurogastroenterol Motil 2008;20:285–290.
89. Gulyas AE and Salazar-Grueso EF. Pharyngeal dysmotility in a patient with Wilson's disease. Dysphagia 1988;2:230–234.
90. Haggstrom G and Hirschowitz BI. Disordered esophageal motility in Wilson's disease. J Clin Gastroenterol 1980;2:273–275.
91. Walshe JM and Yealland M. Wilson's disease: The problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992;55:692–696.
92. Svetel M, Kozic D, Stefanova E, et al. Dystonia in Wilson's disease. Mov Disord 2001;16:719–723.
93. Basir A, Bougteba A, and Kissani N. Torticollis révélant une maladie de Wilson. Arch Pediatr 2009;16:402–404.
94. Dening TR, Berrios GE, and Walshe JM. Wilson disease and epilepsy. Brain 1988;111:1139–1155.
95. Huang C-C and Chu N-S. Psychosis and epileptic seizures in Wilson's disease with predominantly white matter lesions in the frontal lobe. Parkinsonism Relat Disord 1995;1:53–58.
96. Mingazzini G. Über das Zwangsweinen und-lachen. Klin Wochenschr (Wien) 1928;41:998–1002.
97. Firneisz G, Szalay F, Halasz P, et al. Hypersomnia in Wilson's disease: an unusual symptom in an unusual case. Acta Neurol Scand 2000;101:286–288.
98. Portala K, Westermark K, Ekselius L, et al. Sleep in patients with treated Wilson's disease. A questionnaire study. Nord J Psychiatry 2002;56:291–297.
99. Nair KR and Pillai PG. Trunkal myoclonus with spontaneous priapism and seminal ejaculation in Wilson's disease. J Neurol Neurosurg Psychiatry 1990;53:174.
100. Bhattacharya K, Velickovic M, Schilsky M, et al. Autonomic cardiovascular reflexes in Wilson's disease. Clin Auton Res 2002;12:190–192.
101. Meenakshi-Sundaram S, Taly AB, Kamath V, et al. Autonomic dysfunction in Wilson's disease: A clinical and electrophysiological study. Clin Auton Res 2002;12:185–189.
102. Akil M, Schwartz JA, Dutchak D, et al. The psychiatric presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci 1991;3:377–382.
103. Srinivas K, Sinha S, Taly AB, et al. Dominant psychiatric manifestations in Wilson's disease: A diagnostic and therapeutic challenge! J Neurol Sci 2008;266:104–108.
104. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 2000;223:39–46.
105. Walshe JM. Missed Wilson's disease. Lancet 1975;ii:405–406.
106. Akil M and Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol 1995;65:171–178.
107. Shanmugiah A, Sinha S, Taly AB, et al. Psychiatric manifestations in Wilson's disease: a cross-sectional analysis. J Neuropsychiatry Clin Neurosci 2008;20:81–85.
108. Oder W, Grimm G, Kollegger H, et al. Neurological and neuropsychiatric spectrum of Wilson's disease: A prospective study of 45 cases. J Neurol 1991;238:281–287.
109. Machado AC
, Deguti MM, Caixeta L, et al. Mania as the first manifestation of Wilson's disease. Bipolar Disord 2008;10:447–450.
110. Kumawat BL, Sharma CM, Tripathi G, et al. Wilson's disease presenting as isolated obsessive-compulsive disorder. Indian J Med Sci 2007;61:607–610.
111. Matarazzo EB. Psychiatric features and disturbance of circadian rhythm of temperature, pulse, and blood pressure in Wilson's disease. J Neuropsychiatry Clin Neurosci 2002;14:335–339.
112. Seniow J, Bak T, Gajda J, et al. Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. Mov Disord 2002;17:1077–1083.
113. Portala K, Westermark K, von Knorring L, et al. Psychopathology in treated Wilson's disease determined by means of CPRS expert and self-ratings. Acta Psychiatr Scand 2000;101:104–109.
114. Portala K, Levander S, Westermark K, et al. Pattern of neuropsychological deficits in patients with treated Wilson's disease. Eur Arch Psychiatry Clin Neurosci 2001;251:262–268.
115. Portala K, Westermark K, Ekselius L, et al. Personality traits in treated Wilson's disease determined by means of the Karolinska Scales of Personality (KSP). Eur Psychiatry 2001;16:362–371.
116. Rathbun JK. Neuropsychological aspects of Wilson's disease. Int J Neurosci 1996;85:221–229.
117. Tarter RE, Switala J, Carra J, et al. Neuropsychological impairment associated with hepatolenticular degeneration (Wilson's disease) in the absence of overt encephalopathy. Int J Neurosci 1987;37:67–71.
118. Scheinberg IH, Sternlieb I, and Richman J. Psychiatric manifestations in patients with Wilson's disease. In Bergsma D, Scheinberg IH, Sternlieb I (eds). Wilson's Disease: Birth Defects, Original Article Series. Vol 4. New York: The National Foundation—March of Dimes, 1968, pp. 85–87.
119. Dening TR. Psychiatric aspects of Wilson's disease. Br J Psychiatry 1985;147:677–682.
120. Davis EJ and Borde M. Wilson's disease and catatonia. Br J Psychiatry 1993;162:256–259.
121. Kaul A and McMahon D. Wilson's disease and offending behavior: A case report. Med Sci Law 1993;33:353–358.
122. Gwirtsman HE, Prager J, and Henkin R. Case report of anorexia nervosa associated with Wilson's disease. Int J Eat Disord 1993;13:241–244.
123. Spyridi S, Diakogiannis I, Michaelides M, et al. Delusional disorder and alcohol
abuse in a patient with Wilson's disease. Gen Hosp Psychiatry 2008;30:585–586.
124. Wiebers DO, Hollenhorst RW, and Goldstein NP. The ophthalmologic manifestations of Wilson's disease. Mayo Clin Proc 1977;52:409–416.
125. Johnson RD and Campbell RJ: Wilson's disease: Electron microscopic, X-ray energy spectroscopic and atomic absorption spectroscopic studies of corneal copper
deposition and distribution. Lab Invest 1982;46:546–569.
126. Innes JR, Strachan IM, and Triger DR. Unilateral Kayser-Fleischer ring. Br J Ophthalmol 1979;70:469–470.
127. Suvarna JC. Kayser-Fleischer ring. J Postgrad Med 2008;54:238–240.
128. Tauber J and Steinert RF. Pseudo-Kayser-Fleischer ring of the cornea associated with non-Wilsonian liver disease: A case report and literature review. Cornea 1993;12:74–77.
129. Sussman W and Scheinberg IH. Disappearance of Kayser-Fleischer rings. Effects of penicillamine
. Arch Ophthalmol 1969;82:738–741.
130. Fleming CR, Dickson ER, Wahner HW, et al. Pigmented corneal rings in non-Wilsonian liver disease. Ann Intern Med 1977;86:285–288.
131. Frommer D, Morris J, Sherlock S, et al. Kayser-Fleischer-like rings in patients without Wilson's disease. Gastroenterology 1977;72:1331–1335.
132. Kaplinsky C, Sternlieb I, Javitt N, et al. Familial cholestatic cirrhosis associated with Kayser-Fleischer rings. Pediatrics 1980;65:782–788.
133. Garmizo G and Frauens BJ. Corneal copper
deposition secondary to oral contraceptives. Optom Vis Sci 2008;85:E802-E807.
134. Stephenson S. Cases illustrating an unusual form of corneal opacity due to the long-continued application of copper
sulphate to the palpebral conjunctiva. Trans Ophthalmol Soc UK 1902;23:25–27.
135. Goodman SI, Rodgerson DO, and Kaufman J. Hypercupremia in a patient with multiple myeloma. J Lab Clin Med 1967;70:57–62.
136. Lewis RA, Falls HF, and Troyer DO. Ocular manifestations of hypercupremia associated with multiple myeloma. Arch Ophthalmol 1995;93:1050–1053.
137. Martin NF, Kincaid MC, Stark WJ, et al. Ocular copper
deposition associated with pulmonary carcinoma, IgG monoclonal gammopathy and hypercupremia: A clinicopathologic correlation. Ophthalmology 1983;90:110–116.
138. Giorgio AJ, Cartwright GE, and Wintrobe MM. Pseudo-Kayser-Fleischer rings. Arch Intern Med 1964;113:817–818.
139. Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007;86:112–121.
140. Siemerling E and Oloff H. Pseudosklerose (Westphal-Strümpell) mit Cornealring (Kayser-Fleischer) und doppelseitiger Scheinkatarakt, die nur bei seitlicher Beleuchtnung sichtbar ist und die der nach Verletzung durch Kupfersplitter entstehenden Katarakt ähnlich ist. Klin Wochenschr 1922;1:1087–1089.
141. Cairns JE, Williams HP, and Walshe JM. “Sunflower cataract” in Wilson's disease. Br Med J 1969;3:95–96.
142. Goldberg MF and von Noorden GK. Ophthalmologic findings in Wilson's hepatolenticular degeneration: With emphasis on ocular motility. Arch Ophthalmol 1966;75:162–170.
143. Ingster-Moati I, Quoc EB, Pless M, et al. Ocular motility and Wilson's disease: a study on 34 patients. J Neurol Neurosurg Psychiatry 2007;78:1199–1201.
144. Lesśniak M, Czlonkowska A, and Seniów J. Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson's disease. Mov Disord 2008;14:2067–2073.
145. Pillat A. Changes in the eyegrounds in Wilson's disease (pseudosclerosis). Am J Ophthalmol 1933;16:1–6.
146. Walsh FB and Hoyt WF. Clinical Neuroophthalmology, 3rd ed. Vol 2. Baltimore: Williams & Wilkins, 1969, p. 1140.
147. Gow PJ, Peacock SE, and Chapman RW. Wilson's disease presenting with rapidly progressive visual loss: another neurologic manifestation of Wilson's disease? J Gastroenterol Hepatol 2001;16:699–701.
148. Lennox G and Jones R. Gaze distractibility in Wilson's disease. Ann Neurol 1989;25:415–417.
149. Keane JR. Lid-opening apraxia in Wilson's disease. J Clin Neuroophthalmol 1988;8:31–33.
150. Lee MS, Kim YD, and Lyoo CH. Oculogyric crisis as an initial manifestation of Wilson's disease. Neurology 1999;52:1714–1715.
151. Dastur DK, Manghani DK, and Wadia NH. Wilson's disease in India. I. Geographic, genetic, and clinical aspects in 16 families. Neurology 1968;18:21–31.
152. Tu JB. A genetic, biochemical and clinical study of Wilson's disease among Chinese in Taiwan. Acta Paediatr Sin 1963;4:81–84.
153. Xu XH, Yang BX, and Feng YK. Wilson's disease (hepatolenticular degeneration): Clinical analysis of 80 cases. Chin Med J 1981;94:673–678.
154. Saito T. Presenting symptoms and natural history of Wilson's disease. Eur J Pediatr 1987;146:261–265.
155. Golding DN and Walshe JM. Arthropathy of Wilson's disease: Study of clinical and radiological features in 32 patients. Ann Rheum Dis 1977;36:99–111.
156. Canelas HM, Carvalho N, Scaff M, et al. Osteoarthropathy of hepatolenticular degeneration. Acta Neurol Scand 1978;57:481–487.
157. Yarze JC, Martin P, Munoz SJ, et al. Wilson's disease: Current status. Am J Med 1992;92:643–654.
158. Selimoglu MA, Ertekin V, Doneray H, et al. Bone mineral density of children with Wilson disease: Efficacy of penicillamine
and zinc therapy. J Clin Gastroenterol 2008;42:194–198.
159. Feller E and Schumacher HR: Osteoarticular changes in Wilson's disease. Arthritis Rheum 1972;15:259–266.
160. Balint G, Szebenyi B: Hereditary disorders mimicking and/or causing premature osteoarthritis. Baillieres Best Pract Res Clin Rheumatol 2000;14:219–250.
161. Mindelzun R, Elkin M, Scheinberg IH, et al. Skeletal changes in Wilson's disease: A radiological study. Radiology 1970;94:127–132.
162. Kramer U, Weinberger A, Yarom R, et al. Synovial copper
deposition as a possible explanation of arthropathy in Wilson's disease. Bull Hosp Jt Dis 1993;52:46–49.
163. McIntyre N, Clink HM, Levi AJ, et al. Hemolytic anemia in Wilson's disease. N Engl J Med 1967;276:439–444.
164. Sternlieb I. Wilson's disease: Indications for liver transplants. Hepatology 1984;4:15S–17S.
165. Meyer RJ and Zalusky R. The mechanisms of hemolysis in Wilson's disease: Study of a case and review of the literature. Mt Sinai J Med 1977;44:530–538.
166. Forman SJ, Kumar KS, Redeker AG, et al. Hemolytic anemia in Wilson disease: Clinical findings and biochemical mechanisms. Am J Hematol 1980;9:269–275.
167. Lee JJ, Kim HJ, Chung IJ, et al. Acute hemolytic crisis with fulminant hepatic failure as the first manifestation of Wilson's disease: A case report. J Korean Med Sci 1998;13:548–550.
168. Druml W, Laggner AN, Lenz K, et al. Pancreatitis in acute hemolysis. Ann Hematol 1991;63:39–41.
169. Prella M, Baccala R, Horisberger JD, et al. Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319. Br J Haematol 2001;114:230–232.
170. Donfrid M, Jankovic G, Strahinja R, et al. Idiopathic thrombocytopenia associated with Wilson's disease. Hepatogastroenterology 1998;45:1774–1776.
171. Wiebers DO, Wilson DM, McLeod RA, et al. Renal stones in Wilson's disease. Am J Med 1979;67:249–254.
172. Hoppe B, Neuhaus T, Superti-Furga A, et al. Hypercalciuria and nephrocalcinosis, a feature of Wilson's disease. Nephron 1993;65:460–462.
173. Sozeri E, Feist D, Ruder H, et al. Proteinuria and other renal functions in Wilson's disease. Pediatr Nephrol 1997;11:307–311.
174. Leu ML, Strickland GT, Wang CC, et al. Skin pigmentation in Wilson's disease. J Am Med Assoc 1970;211:1542–1543.
175. Bearn AG and McKusick VA
. Azure lunulae: An unusual change in the fingernails in two patients with hepatolenticular degeneration (Wilson's disease). J Am Med Assoc 1958;166:904–906.
176. Ezzo JA, Rowley JF, and Finnegin JV. Hepatolenticular degeneration associated with acanthosis nigricans. Arch Intern Med 1957;100:827–832.
177. Schaefer M, Schellenberg M, Merle U, et al. Wilson protein expression, copper
excretion and sweat production in sweat glands of Wilson disease patients and controls. BMC Gastroenterol 2008;8:29.
178. Scheinberg IH and Sternlieb I. Wilson's disease. Annu Rev Med 1965;16:119–134.
179. Lau JY, Lai CL, Wu PC, et al. Wilson's disease: 35 years' experience. Q J Med 1990;75:597–605.
180. Erkan T, Aktuglu C, Gulcan EM, et al. Wilson disease manifested primarily as amenorrhea and accompanying thrombocytopenia. J Adolesc Health 2002;31:378–380.
181. Sternlieb I and Scheinberg IH. Wilson's disease. In Wright R, Alberti KGM, Karran S, et al. (eds). Liver and Biliary Disease. London: Bailliere Tindall, 1985, pp. 949–961.
182. McIntyre N. Neurological Wilson's disease. Q J Med 1993;86:349–350.
183. Houwen RHJ. Copper
: Two sides of the same coin. Neth J Med 2008;66:325–326.
184. Snow B. Laboratory diagnosis and monitoring of Wilson's disease. In Neurological Aspects of Wilson's Disease, American Academy of Neurology Course 411. 1995, pp. 25–30.
185. Smallwood RA, Williams HA, and Rosenauer VM. Liver copper
levels in liver disease: Studies using neutron activation analysis. Lancet 1968;ii:1310–1313.
186. Benson GD. Hepatic copper
accumulation in primary biliary cirrhosis. Yale J Biol Med 1979;52:83–88.
187. Evans J, Newman S, and Sherlock S. Liver copper
levels in intrahepatic cholestasis of childhood. Gastroenterology 1978;75:875–878.
188. Tanner MS, Portmann B, Mowat AP, et al. Increased hepatic copper
concentration in Indian childhood cirrhosis. Lancet 1979;i:1203–1205.
189. LaRusso NF, Summerskill WH, and McCall JT. Abnormalities of chemical tests for copper
metabolism in chronic active liver disease: Differentiation from Wilson's disease. Gastroenterology 1976;70:653–655.
190. Sternlieb I, Giblin DR, and Scheinberg IH. Wilson's disease. In Marsden CD, Fahn S (eds). Movement Disorders. Vol 2. London: Butterworth, 1987, pp 288–302.
191. Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper
determination in patients with Wilson's disease. Clin Gastroenterol Hepatol 2005;3:811–818.
192. Willeit J and Kiechl SG. Wilson's disease with neurologic impairment but no Kayser-Fleischer rings. Lancet 1991;337:1426.
193. Vidaud D, Assouline B, Lecoz P, et al. Misdiagnosis revealed by genetic linkage analysis in a family with Wilson disease. Neurology 1996;46:1485–1486.
194. Frommer DJ. Urinary copper
excretion and hepatic copper
concentrations in liver disease. Digestion 1981;21:169–178.
195. Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: A diagnostic challenge. Gastroenterology 1997;113:212–218.
196. Foruny JR, Boixeda D, López-Sanroman A, et al. Usefulness of penicillamine-stimulated urinary copper
excretion in the diagnosis of adult Wilson's disease. Scand J Gastroenterol 2008;43:597–603.
197. Müller T, Koppikar S, Taylor RM, et al. Re-evaluation of the penicillamine
challenge test in the diagnosis of Wilson's disease in children. J Hepatol 2007;47:270–276.
198. Cumings JN. Trace metals in the brain and in Wilson's disease. J Clin Pathol 1968;21:1–7.
199. Stremmel W, Meyerrose K-W, Niederau C, et al. Wilson disease: Clinical presentation, treatment, and survival. Ann Intern Med 1991;115:720–726.
200. Twomey PJ, Viljoen A, Reynolds TM, et al. Non-ceruloplasmin-bound copper
in routine clinical practice in different laboratories. J Trace Elem Med Biol 2008;22:50–53.
201. McMillin GA, Travis JJ, and Hunt JW. Direct measurement of free copper
in serum or plasma ultrafiltrate. Am J Clin Pathol 2009;131:160–165.
202. Sternlieb I and Scheinberg IH. The role of radiocopper in the diagnosis of Wilson's disease. Gastroenterology 1979;77:138–142.
203. Weisner B, Hartard C, and Dieu C. CSF copper
concentration: A new parameter for diagnosis and monitoring therapy of Wilson's disease with cerebral manifestation. J Neurol Sci 1987;79: 229–237.
204. Hartard C, Weisner B, Dieu C, et al. Wilson's disease with cerebral manifestation: Monitoring therapy by CSF copper
concentration. J Neurol 1993;241:101–107.
205. Stuerenburg HJ. CSF copper
concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm 2000;107:321–329.
206. Thuomas KA, Aquilonius SM, Bergstrom K, et al. Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:134–141.
207. Roh JK, Lee TG, Wie BA, et al. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. Neurology 1994;44:1064–1068.
208. Selwa LM, Vanderzant CW, Brunberg JA, et al. Correlation of evoked potential and MRI findings in Wilson's disease. Neurology 1993;43:2059–2064.
209. Magalhaes ACA, Caramelli P, Menezes JR, et al. Wilson's disease: MRI with clinical correlation. Neuroradiology 1994;36:97–100.
210. Alanen A, Komu M, Penttinen M, et al. Magnetic resonance imaging and proton MR spectroscopy in Wilson disease. Br J Radiol 1999;72:749–756.
211. Hitoshi S, Iwata M, and Yoshikawa K. Midbrain pathology of Wilson's disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 1991;54:624–626.
212. Liebeskind DS, Wong S, and Hamilton RH. Faces of the giant panda and her cub: MRI correlates of Wilson's disease. J Neurol Neurosurg Psychiatry 2003;74:682.
213. Sener RN. The claustrum on MRI: Normal anatomy, and the bright claustrum as a new sign in Wilson's disease. Pediatr Radiol 1993;23:594–596.
214. Das SK and Ray K. Wilson's disease: an update. Nat Clin Pract Neurol 2006;2:482–493.
215. Sener RN. Diffusion MRI findings in Wilson's disease. Comput Med Imaging Graph 2003;27:17–21.
216. Jayasundar R, Sahani AK, Gaikwad S, et al. Proton MR spectroscopy of basal ganglia in Wilson's disease: Case report and review of literature. Magn Reson Imaging 2002;20:131–135.
217. Tarnacka B, Szeszkowski W, Golebiowski M, et al. MR spectroscopy in monitoring the treatment of Wilson's disease patients. Mov Disord 2008;23:1560–1566.
218. Hawkins RA, Mazziotta JC, and Phelps ME. Wilson's disease studied with FDG and positron emission tomography. Neurology 1987;37:1707–1711.
219. Hefter H, Kuwert T, Herzog H, et al. Relationship between striatal glucose consumption and copper
excretion in patients with Wilson's disease treated with D-penicillamine. J Neurol 1993;241:49–53.
220. Snow BJ, Bhatt MH, Martin WRW, et al. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:12–17.
221. Topcu M, Topcuoglu MA, Kose G, et al. Evoked potentials in children with Wilson's disease. Brain Dev 2002;24:276–280.
222. Grimm G, Madl C, Katzenschlager R, et al. Detailed evaluation of evoked potentials in Wilson's disease. Electroencephalogr Clin Neurophysiol 1992;82:119–124.
223. Bartova P, Skoloudik D, Bar M, et al. Transcranial sonography in movement disorders. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:251–258.
224. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr 1993;12:527–530.
225. Ebadi M, Paliwal VK, Takahashi T, et al. Zinc metallothionein in mammalian brain. UCLA Symp Mol Cell Biol 1989;98:257–267.
226. Ebadi M. Metallothionein and other zinc-binding proteins in brain. Methods Enzymol 1991;205:363–387.
227. Day FA, Panemangelore M, and Brady FO. In vivo and ex vivo effects of copper
on rat liver metallothionein. Proc Soc Exp Biol Med 1981;168:306–310.
228. Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983;99:314–320.
229. Hall AC
, Young BW, and Bremner I. Intestinal metallothionein and the mutual antagonism between copper
and zinc in the rat. J Inorg Biochem 1979;11:57–66.
230. Brewer GJ and Yuzbasiyan-Gurkan V. Wilson's disease. In Klawans HK, Goetz CG, Tanner CM (eds). Textbook of Clinical Neuropharmacology and Therapeutics. New York: Raven Press, 1992, pp. 191–205.
231. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opin Pharmacother 2001;2:1473–1477.
232. Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY, et al. Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med 1989;114:633–638.
233. Schilsky ML. Treatment of Wilson's disease: What are the relative roles of penicillamine
, and zinc supplementation? Curr Gastroenterol Rep 2001;3:54–59.
234. Rossaro L, Sturniolo GC, Giacon G, et al. Zinc therapy in Wilson's disease: Observations in five patients. Am J Gastroenterol 1990;85:665–668.
235. Hoogenraad T. Wilson's Disease. London: WB Saunders, 1996.
236. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc XVI: Treatment during the pediatric years. J Lab Clin Med 2001;137:191–198.
237. Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc XVII: Treatment during pregnancy. Hepatology 2000;31:364–370.
238. Subramanian I, Vanek ZF, and Bronstein JM. Diagnosis and treatment of Wilson's disease. Curr Neurol Neurosci Rep 2002;2:317–323.
239. Simon SR, Branda RF, Tindle BH, et al. Copper
deficiency and sideroblastic anemia associated with zinc ingestion. Am J Hematol 1988;28:181–183.
240. Brewer GJ, Yuzbasiyan-Gurkan V, and Lee D-Y. Molecular genetics and zinc-copper interactions in human Wilson's disease and canine copper
toxicosis. In Prasad AS (ed). Essential and Toxic Trace Elements in Human Health and Disease: An Update. New York: Wiley-Liss, 1992, pp. 129–145.
241. Hooper PL, Visconti L, Garry PJ, et al. Zinc lowers high-density lipoprotein-cholesterol levels. J Am Med Assoc 1980;244:1960–1961.
242. Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD, et al. Treatment of Wilson's disease with zinc: V. Changes in serum levels of lipase, amylase and alkaline phosphatase in Wilson's disease patients. J Lab Clin Med 1989;114:520–526.
243. Walshe JM. Penicillamine
: The treatment of first choice for patients with Wilson's disease. Mov Disord 1999;14:545–550.
244. Brewer GJ. Penicillamine
should not be used as initial therapy in Wilson's disease. Mov Disord 1999;14:551–554.
245. LeWitt PA. Penicillamine
as a controversial treatment for Wilson's disease. Mov Disord 1999;14:555–556.
246. Lang CJG, Rabas-Kolminsky P, Engelhardt A, et al. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol 1993;50:1007–1008.
247. Walshe JM and Munro NAR. Zinc induced deterioration in Wilson's disease aborted by treatment with penicillamine
, and a novel zero copper
diet. Arch Neurol 1995;52:10–11.
248. Castilla-Higuero L, Romero-Gomez M, Suarez E, et al. Acute hepatitis after starting zinc therapy in a patient with presymptomatic Wilson's disease. Hepatology 2000;32:877.
249. Mishra D, Kalra V, and Seth R. Failure of prophylactic zinc in Wilson's disease. Indian Pediatr 2008;45:151–153.
250. Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs 2009;18:89–97.
251. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545–554.
252. George GN, Pickering IJ, Harris HH, et al. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease. J Am Chem Soc 2003;125:1704–1705.
253. Zhang L, Lichtmannegger J, Summer KH, et al. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease. Biochemistry 2009;48:891–897.
254. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48:42–47.
255. Brewer GJ, Johnson V, Dick RD, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53:1017–1025.
256. Spence JA, Suttle NF, Wenham G, et al. A sequential study of the skeletal abnormalities, which develop in rats given a small dietary supplement of ammonium tetrathiomolybdate. J Comp Pathol 1980;90:139–153.
257. Walshe JM and Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med 1993;86:197–204.
258. Walshe JM. Penicillamine
: A new oral therapy for Wilson's disease. Am J Med 1956;21:487–495.
259. Deiss A. Treatment of Wilson's disease. Ann Intern Med 1983;99:398–399.
260. Goldstein NP, Ewert JC, Randall RV, et al. Psychiatric aspects of Wilson's disease (hepatolenticular degeneration): Results of psychometric tests during long-term therapy. Am J Psychiatry 1968;124:1555–1561.
261. Williams FJB and Walshe JM. Wilson's disease. An analysis of the cranial computerized tomographic appearances found in patients and the changes in response to treatment with chelating agents. Brain 1981;104:735–752.
262. Nazer H, Brismar J, Al-Kawi MZ, et al. Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:130–133.
263. Schuna A, Osman MA, Patel RB, et al. Influence of food on the bioavailability of penicillamine
. J Rheumatol 1983;10:95–97.
264. Marsden CD. Wilson's disease. Q J Med 1987;248:959–966.
265. Gibbs KR and Walshe JM. Interruption of the tryptophan-nicotinic acid pathway by penicillamine-induced pyridoxine
deficiency in patients with Wilson's disease and in experimental animals. Ann N Y Acad Sci 1969;111:158–169.
266. Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurological syndrome in patients with Wilson's disease with initial penicillamine
therapy. Arch Neurol 1987;44:490–493.
267. Svetel M, Sternic N, Pejovic S, et al. Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease. Mov Disord 2001;16:568–569.
268. Glass JD, Reich SG, and DeLong MR. Wilson's disease: Development of neurological disease after beginning penicillamine
therapy. Arch Neurol 1990;47:595–596.
269. Brewer GJ, Turkay A, and Yuzbasiyan-Gurkan V. Development of neurologic symptoms in a patient with asymptomatic Wilson's disease. Arch Neurol 1994;51:304–305.
270. Sternlieb I and Scheinberg IH. Penicillamine
therapy in hepatolenticular degeneration. J Am Med Assoc 1964;189:748–754.
271. Haggstrom GC, Hirschowitz BI, and Flint A. Long-term penicillamine
therapy for Wilson's disease. South Med J 1980;73:530–531.
272. Chan C-Y and Baker AL. Penicillamine
hypersensitivity: Successful desensitization of a patient with severe hepatic Wilson's disease. Am J Gastroenterol 1994;89:442–443.
273. Corcos JM, Soler-Bechera J, Mayer K, et al. Neutrophilic agranulocytosis during administration of penicillamine
. J Am Med Assoc 1964;189:265–268.
274. Hirschman SZ and Isselbacher KJ. The nephrotic syndrome as a complication of penicillamine
therapy of hepatolenticular degeneration (Wilson's disease). Ann Intern Med 1965;62:1297–1300.
275. Sternlieb I, Bennett B, and Scheinberg IH. D-Penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975;82:673–675.
276. Walshe JM. Penicillamine
and the SLE syndrome. J Rheumatol 1981;8(suppl 7):155–160.
277. Czlonkowska A. Myasthenia syndrome during penicillamine
treatment. Br Med J 1975;2:726–727.
278. Bigger JF. Retinal hemorrhages during penicillamine
therapy of cystinuria. Am J Ophthalmol 1968;66:954–955.
279. Hanukoglu A, Curiel B, Berkowitz D, et al. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease. J Pediatr 2008;153:864–866.
280. Shoulson I, Goldblatt D, Plassche W, et al. Some therapeutic observations in Wilson's disease. Adv Neurol 1983;37:239–246.
281. Henkin RI, Keiser HR, Jaffe IA, et al. Decreased taste sensitivity after D-penicillamine reversed by copper
administration. Lancet 1967;ii:1268–1271.
282. Proesman W, Jaeken J, and Eckels R. D-Penicillamine induced IgA deficiency in Wilson's disease. Lancet 1976;ii:804–805.
283. Sternlieb I, Fisher M, and Scheinberg IH. Penicillamine-induced skin lesions. J Rheumatol 1981;8(suppl 7):149–154.
284. Nimni ME. Mechanism of inhibition of collagen
cross-linking by penicillamine
. Proc R Soc Med 1977;70(suppl 3):65–72.
285. Morris JJ, Seifter E, Rettura G, et al. Effect of penicillamine
upon wound healing. J Surg Res 1969;9:143–149.
286. Kirsch N and Hukill PB. Elastosis perforans serpiginosa by penicillamine
. Electron microscopic observations. Arch Dermatol 1977;113:630–635.
287. Pass F, Goldfischer S, Sternlieb I, et al. Elastosis perforans serpiginosa after penicillamine
therapy for Wilson's disease. Arch Dermatol 1973;108:713–715.
288. Eisenberg E, Ballow M, Wolfe SH, et al. Pemphigus-like mucosal lesions: A side effect of penicillamine
therapy. Oral Surg Oral Med Oral Pathol 1981;51:409–414.
289. Bennett RA and Harbilas E. Wilson's disease with aseptic meningitis and penicillamine-related cheilosis. Arch Intern Med 1967;120:374–376.
290. Walshe JM. The management of penicillamine
nephropathy in Wilson's disease: A new chelating agent. Lancet 1969;ii:1401–1402.
291. Walshe JM. Assessment of the treatment of Wilson's disease with triethylene tetramine 2HCl (Trien 2HCl). In Sarker B (ed). Biological Aspects of Metal Related Diseases. New York: Raven Press, 1983, pp. 243–261.
292. Walshe JM. Treatment of Wilson's disease with trientine
(triethylene tetramine) dihydrochloride. Lancet 1982;i:643–647.
293. Walshe JM. Copper
chelation in patients with Wilson's disease: A comparison of penicillamine
and triethylene tetramine hydrochloride. Q J Med 1973;42:441–452.
294. Sarkar B, Sass-Kortsak A, Clarke R, et al. A comparative study of in vitro and in vivo interaction of D-penicillamine and triethylenetetramine with copper
. Proc R Soc Med 1977;70(suppl 3):13–18.
295. Fox AN and Schilsky M. Once daily trientine
for maintenance therapy of Wilson disease. Am J Gastroenterol 2008;103:494–495.
296. Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Hematol 1993;83:166–168.
297. Brewer GJ. Wilson's disease. Curr Treat Options Neurol 2000;2:193–204.
298. Schilsky ML, Scheinberg IH, and Sternlieb I. Liver transplantation for Wilson's disease: Indications and outcome. Hepatology 1994;19:583–587.
299. Rela M, Heaton ND, Vougas V, et al. Orthotopic liver transplantation for hepatic complications of Wilson's disease. Br J Surg 1993;80:909–911.
300. Shafer DF and Shaw BW Jr. Fulminant hepatic failure and orthotopic liver transplantation. Semin Liver Dis 1989;9:189–194.
301. Cheng F, Li GO, Zhang F, et al. Outcomes of living-related liver transplantation for Wilson's disease: a single-center experience in China. Transplantation 2009;87:751–757.
302. Yoshitoshi EY, Takada Y, Oike F, et al. Long-term outcomes for 32 cases of Wilson's disease after living-donor liver transplantation. Transplantation 2009;87:261–267.
303. Sen S, Felldin M, Steiner C, et al. Albumin
dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson's disease. Liver Transpl 2002;8:962–967.
304. Kreymann B, Seige M, Schweigart U, et al. Albumin
dialysis: Effective removal of copper
in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins. J Hepatol 1999;31:1080–1085.
305. Chiu A, Tsoi NS, and Fan ST. Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease. Liver Transpl 2008;14:1512–1516.
306. Collins KL, Roberts EA, Adeli K, et al. Single pass albumin
dialysis (SPAD) in fulminant Wilsonian liver failure: A case report. Pediatr Nephrol 2008;23:1013–1016.
307. Kiss JE, Berman D, and Van Thiel D. Effective removal of copper
by plasma exchange in fulminant Wilson's disease. Transfusion 1998;38:327–331.
308. Jhang JS, Schilsky ML, Lefkowitch JH, et al. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apher 2007;22:10–14.
309. Hursitoglu M, Kara O, Cikrikcioglu MA, et al. Clinical improvement of a patient with severe Wilson's disease after a single session of therapeutic plasma exchange. J Clin Apher 2009;24:25–27.
310. Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001;47:471–475.
311. Chen CL and Kuo YC. Metabolic effects of liver transplantation in Wilson's disease. Transplant Proc 1993;25:2944–2947.
312. Pabón V, Dumortier J, Gincul R, et al. Long-term results of liver transplantation for Wilson's disease. Gastroenterol Clin Biol 2008;32:378–381.
313. Litwin T, Gromadzka G, and Czlonkowska A. Neurological presentation of Wilson's disease in a patient after liver transplantation. Mov Disord 2008;23:743–746.
314. Komatsu H, Fujisawa T, Inui A, et al. Hepatic copper
concentration in children undergoing living related liver transplantation due to Wilsonian fulminant hepatic failure. Clin Transplant 2002;16:227–232.
315. Mason AL, Marsh W, and Alpers DH. Intractable neurological Wilson's disease treated with orthotopic liver transplantation. Dig Dis Sci 1993;38:1746–1750.
316. Stracciari A, Tempestini A, Borghi A, et al. Effect of liver transplantation on neurological manifestations in Wilson disease. Ar ch Neurol 2000;57:384–386.
317. Pal PK, Sinha S, Pillai S, et al. Successful treatment of tremor in Wilson's disease by thalamotomy: a case report. Mov Disord 2007;22:2287–2290.
318. Malhi H, Irani AN, Volenberg I, et al. Early cell transplantation in LEC rats modeling Wilson's disease eliminates hepatic copper
with reversal of liver disease. Gastroenterology 2002;122:438–447.
319. Ha-Hao D, Merle U, Hofmann C, et al. Chances and shortcomings of adenovirus-mediated ATP7B gene transfer in Wilson disease: Proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 2002;40:209–216.